Caisse DE Depot ET Placement DU Quebec Has $36.74 Million Stock Position in argenex SE $ARGX

Key Points

• Caisse DE Depot ET Placement DU Quebec increased its holdings in argenex SE by 122.5% in the 1st quarter, acquiring 34,174 shares to bring its total to 62,074 shares.
• Multiple large investors, including Point72 Asset Management and GAMMA Investing, significantly increased their stakes in argenex, with GAMMA investing showing a 53,684.9% increase in holdings.
• The stock of argenex has a market capitalization of $43.34 billion and reported a quarterly EPS of $3.74, beating analysts' expectations by $0.90.

Caisse DE Depot ET Placement DU Quebec lifted its position in argenex SE (NASDAQ:ARGX - Free Report) by 122.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,074 shares of the company's stock after acquiring an additional 34,174 shares during the period. Caisse DE Depot ET Placement DU Quebec owned about 0.10% of argenex worth $36,739,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Rakuten Securities Inc. increased its position in shares of argenex by 56.4% in the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after acquiring an additional 22 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of argenex in the fourth quarter worth approximately $38,000. Golden State Wealth Management LLC purchased a new position in shares of argenex in the first quarter worth approximately $44,000. Brooklyn Investment Group increased its position in shares of argenex by 102.7% in the first quarter. Brooklyn Investment Group now owns 75 shares of the company's stock worth $44,000 after acquiring an additional 38 shares in the last quarter. Finally, Raiffeisen Bank International AG purchased a new position in shares of argenex in the first quarter worth approximately $76,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Trading Up 1.2%

NASDAQ ARGX traded up $8.13 during trading on Friday, reaching $712.20. The company's stock had a trading volume of 353,562 shares, compared to its average volume of 393,011. The stock has a market capitalization of $43.59 billion, a PE ratio of 36.52, a PEG ratio of 0.81 and a beta of 0.39. The business has a 50-day moving average price of $611.18 and a 200-day moving average price of $599.48. argenex SE has a 1-year low of $510.05 and a 1-year high of $716.62.

argenex (NASDAQ:ARGX - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.84 by $0.90. The firm had revenue of $866.79 million during the quarter, compared to analysts' expectations of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. As a group, analysts expect that argenex SE will post 3.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ARGX has been the subject of several research reports. Citigroup restated a "buy" rating on shares of argenex in a report on Wednesday, May 21st. Morgan Stanley raised their price target on shares of argenex from $700.00 to $766.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Jefferies Financial Group set a $818.00 price target on shares of argenex and gave the stock a "buy" rating in a report on Tuesday, August 26th. JMP Securities set a $699.00 price target on shares of argenex in a report on Wednesday, May 14th. Finally, Wedbush restated an "outperform" rating and set a $800.00 price target on shares of argenex in a report on Monday, August 25th. Two equities research analysts have rated the stock with a Strong Buy rating and twenty have issued a Buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $766.50.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.